The drug Prevnar is a vaccine meant to prevent certain types of bacterial meningitis. It is typically administered to infants starting around 2 months of age. In randomized, double-blind clinical trials of Prevnar, infants were randomly divided into two groups. Subjects in group 1 received Prevnar, while subjects in group 2 received a control vaccine. After the first dose, 107 of 710 subjects in the experimental group (group 1) experienced fever as a side effect. After the first dose, 67 of 611 of the subjects in the control group (group 2) experienced fever as a side effect. Does the evidence suggest that a higher proportion of subjects in group 1 experienced fever as a side effect than subjects in group 2 at the α = 0.05 level of significance?